Your browser is no longer supported. Please, upgrade your browser.
Settings
CUR Neuralstem, Inc. daily Stock Chart
CUR [NASD]
Neuralstem, Inc.
Index- P/E- EPS (ttm)-2.32 Insider Own0.20% Shs Outstand12.69M Perf Week-5.25%
Market Cap52.66M Forward P/E- EPS next Y-2.24 Insider Trans340.27% Shs Float9.34M Perf Month-13.72%
Income-22.00M PEG- EPS next Q-0.73 Inst Own23.70% Short Float9.56% Perf Quarter-3.49%
Sales0.02M P/S3241.63 EPS this Y15.60% Inst Trans48.85% Short Ratio6.41 Perf Half Y18.23%
Book/sh0.88 P/B4.72 EPS next Y0.90% ROA-139.70% Target Price26.00 Perf Year-11.32%
Cash/sh1.32 P/C3.15 EPS next 5Y- ROE-485.90% 52W Range2.47 - 6.19 Perf YTD16.76%
Dividend- P/FCF- EPS past 5Y5.60% ROI- 52W High-32.96% Beta1.99
Dividend %- Quick Ratio3.40 Sales past 5Y- Gross Margin- 52W Low68.02% ATR0.32
Employees10 Current Ratio3.40 Sales Q/Q0.00% Oper. Margin- RSI (14)43.17 Volatility4.18% 9.78%
OptionableYes Debt/Eq0.26 EPS Q/Q27.20% Profit Margin- Rel Volume0.39 Prev Close4.40
ShortableYes LT Debt/Eq0.00 EarningsMay 15 BMO Payout- Avg Volume139.46K Price4.15
Recom2.00 SMA20-4.61% SMA50-13.91% SMA2003.63% Volume54,998 Change-5.68%
Nov-07-16Initiated Aegis Capital Buy
Aug-29-16Initiated ROTH Capital Buy $1.20
Apr-28-15Initiated MLV & Co Buy $6
Feb-18-15Initiated Brean Capital Buy $8
Sep-08-14Initiated H.C. Wainwright Neutral
Jun-25-14Reiterated Aegis Capital Buy $6 → $7
Dec-10-12Reiterated Aegis Capital Buy $3 → $3.50
Aug-23-12Initiated Maxim Group Sell $0.25
Sep-22-11Initiated Morgan Joseph Buy $5
May-23-17 12:36PM  ETFs with exposure to Neuralstem, Inc. : May 23, 2017 Capital Cube
May-17-17 04:05PM  Neuralstem Reports Last Subject Out in Phase 2 Trial of NSI-189 for Major Depressive Disorder GlobeNewswire
May-12-17 10:54AM  Neuralstem, Inc. :CUR-US: Earnings Analysis: Q1, 2017 By the Numbers : May 12, 2017 Capital Cube
May-11-17 04:28PM  ETFs with exposure to Neuralstem, Inc. : May 11, 2017 Capital Cube
08:00AM  Today's Research Reports on Stocks to Watch: MannKind and Neuralstem Accesswire
May-10-17 04:20PM  Neuralstem reports 1Q loss Associated Press +36.18%
04:05PM  Neuralstem Reports First Quarter 2017 Fiscal Results Provides Clinical and Business Update GlobeNewswire
Apr-19-17 02:17PM  ETFs with exposure to Neuralstem, Inc. : April 19, 2017 Capital Cube
Apr-12-17 07:35AM  Neuralstem Expands Phase 1 Safety Trial of NSI-566 Neural Stem Cells in Spinal Injury GlobeNewswire
Apr-05-17 04:35PM  ETFs with exposure to Neuralstem, Inc. : April 5, 2017 Capital Cube
Mar-31-17 08:51AM  NEURALSTEM, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Unregistered Sale of Equity Securiti
Mar-29-17 01:00PM  Neuralstem, Inc. :CUR-US: Earnings Analysis: Q4, 2016 By the Numbers : March 29, 2017 Capital Cube
10:53AM  Neuralstem, Inc. :CUR-US: Earnings Analysis: 2016 By the Numbers : March 29, 2017
Mar-28-17 01:04PM  NEURALSTEM, INC. Financials
Mar-23-17 03:19PM  NEURALSTEM, INC. Files SEC form 8-K, Results of Operations and Financial Condition
07:35AM  Neuralstem Reports Year End 2016 Fiscal Results and Business Update GlobeNewswire
07:03AM  NEURALSTEM, INC. Files SEC form 10-K, Annual Report
Mar-20-17 08:50AM  NEURALSTEM, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Unregistered Sale of Equity Securiti
Mar-17-17 07:03AM  Neuralstem to Present at Oppenheimer 27th Annual Healthcare Conference on March 21 GlobeNewswire
Mar-10-17 05:03PM  NEURALSTEM, INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits
09:30AM  Today's Research Reports on Market Movers: Neuralstem and Real Goods Solar Accesswire
Mar-09-17 07:03AM  Neuralstem Announces Publication of NSI-566 Data in a Rodent Model of Traumatic Brain Injury GlobeNewswire +19.64%
Mar-08-17 07:03AM  Neuralstem to Present at 29th Annual ROTH Conference GlobeNewswire
Feb-28-17 06:57PM  NEURALSTEM, INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits +7.67%
07:03AM  Neuralstem Announces Publication of NSI-189 Preclinical Data in Journal of Cellular Physiology GlobeNewswire
Feb-27-17 06:09AM  NEURALSTEM, INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits +11.40%
Feb-22-17 04:15PM  NEURALSTEM, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits +5.26%
07:03AM  Neuralstem Announces Issuance of U.S. Patent Covering NSI-189 GlobeNewswire
Feb-17-17 12:22PM  Neuralstem, Inc. (CUR) Is Up. Heres Why And What It Means Insider Monkey
09:30AM  Easier Regulatory Environment Could Send Biotech Industry Skyrocketing in 2017: Today's Reports on Neuralstem and Exelixis Accesswire
Feb-16-17 04:06PM  NEURALSTEM, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits +18.55%
07:02AM  Neuralstem Announces Last Subject Enrolled in Phase 2 Trial with NSI-189 for Major Depressive Disorder GlobeNewswire
Feb-13-17 06:58AM  Neuralstem to Present at BIO CEO & Investor Conference GlobeNewswire
Jan-30-17 08:50AM  Founder of Largest U.S. Homebuilder Sells Shares Amid Signs of Housing Recovery & Other Noteworthy Insider Trading at Insider Monkey -6.03%
Jan-19-17 12:45PM  ETFs with exposure to Neuralstem, Inc. : January 19, 2017
Jan-12-17 09:30AM  Latest Reports on ImmunoCellular Therapeutics and Neuralstem as Biotech Industry Scrutiny Grows after President Trump's Comments Accesswire -6.24%
Jan-10-17 04:24PM  A Little Something for Everybody +59.06%
Jan-09-17 07:03AM  Splits Calendar: Neuralstem splits before market open today (1:13 ratio)
Jan-06-17 05:11PM  NEURALSTEM, INC. Files SEC form 8-K, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Other Events, F
01:01PM  Neuralstem Announces a 1-for-13 Reverse Stock Split GlobeNewswire
Jan-04-17 10:52AM  ETFs with exposure to Neuralstem, Inc. : January 4, 2017
Dec-14-16 05:21PM  NEURALSTEM, INC. Files SEC form 8-K, Regulation FD Disclosure
Dec-12-16 07:41AM  NEURALSTEM, INC. Files SEC form 8-K, Unregistered Sale of Equity Securities, Material Modification to Rights of Secur +12.29%
07:38AM  Neuralstem Announces the Closing of $20 Million Strategic Investment from Tianjin Pharmaceutical Group International Holdings Co., LTD. GlobeNewswire
Dec-08-16 02:31PM  ETFs with exposure to Neuralstem, Inc. : December 8, 2016 -6.01%
Nov-30-16 04:06PM  NEURALSTEM, INC. Files SEC form 8-K, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard;
Nov-28-16 12:02PM  ETFs with exposure to Neuralstem, Inc. : November 28, 2016
Nov-14-16 01:10PM  ETFs with exposure to Neuralstem, Inc. : November 14, 2016
Nov-11-16 11:47AM  Neuralstem, Inc. :CUR-US: Earnings Analysis: Q3, 2016 By the Numbers : November 11, 2016 +6.02%
Nov-08-16 04:48PM  NEURALSTEM, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits
08:03AM  NEURALSTEM, INC. Files SEC form 10-Q, Quarterly Report
07:39AM  Neuralstem reports 3Q loss
07:35AM  Neuralstem Reports Third Quarter 2016 Results GlobeNewswire
Nov-07-16 09:37AM  Coverage initiated on Neuralstem by Aegis Capital +6.17%
Nov-02-16 07:35AM  Neuralstem Announces Presentations at Upcoming Scientific Conferences GlobeNewswire
Oct-27-16 01:21PM  ETFs with exposure to Neuralstem, Inc. : October 27, 2016 -9.81%
Oct-21-16 04:07PM  NEURALSTEM, INC. Files SEC form 8-K, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard;
Oct-20-16 04:06PM  NEURALSTEM, INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits +5.52%
07:52AM  Neuralstem Presents NSI-189 Preclinical Neurocognitive Benefits at the Radiation Research Society Annual Meeting GlobeNewswire
Oct-05-16 10:14AM  ETFs with exposure to Neuralstem, Inc. : October 5, 2016
Sep-21-16 04:02PM  NEURALSTEM, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits
08:32AM  Neuralstem Achieves 50% Enrollment in NSI-189 Phase 2 Trial in Major Depressive Disorder GlobeNewswire
Sep-13-16 10:24AM  ETFs with exposure to Neuralstem, Inc. : September 13, 2016 -5.00%
Sep-12-16 02:06PM  NEURALSTEM, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits +7.26%
08:32AM  Neuralstem Presented NSI-189 Preclinical Data in Type 1 and Type 2 Diabetes at the Annual Meeting of the Diabetic Neuropathy Study Group GlobeNewswire
08:03AM  Neuralstem Receives $20,000,000 Strategic Investment from Tianjin Pharmaceutical Group GlobeNewswire
Sep-01-16 01:20PM  NEURALSTEM, INC. Files SEC form 8-K, Submission of Matters to a Vote of Security Holders -6.81%
Aug-30-16 11:05AM  ETFs with exposure to Neuralstem, Inc. : August 30, 2016 +11.48%
Aug-19-16 12:49PM  ETFs with exposure to Neuralstem, Inc. : August 19, 2016
Aug-18-16 10:29AM  Neuralstem, Inc. :CUR-US: Earnings Analysis: Q2, 2016 By the Numbers : August 18, 2016 +5.69%
Aug-11-16 05:13PM  Neuralstem reports 2Q loss
04:07PM  NEURALSTEM, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits
04:05PM  Neuralstem Reports Second Quarter 2016 Results and Provides Business and Clinical Updates GlobeNewswire
Aug-09-16 04:37PM  NEURALSTEM, INC. Files SEC form 8-K, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; -7.14%
Jul-21-16 01:55PM  ETFs with exposure to Neuralstem, Inc. : July 21, 2016
Jul-18-16 09:15AM  Stocks Coverage on the Healthcare Sector for Biostar Pharma, GlobeImmune, Neuralstem, and GW Pharma
Jun-23-16 04:47PM  NEURALSTEM, INC. Files SEC form 8-K, Other Events
Jun-21-16 04:40PM  NEURALSTEM, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits
08:15AM  Neuralstem Announces NSI-189 Shows Enhancement of Long-Term Potentiation In Vitro GlobeNewswire
Jun-20-16 04:27PM  NEURALSTEM, INC. Files SEC form 8-K, Submission of Matters to a Vote of Security Holders +6.00%
Jun-16-16 04:01PM  NEURALSTEM, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Change in Directors or Principal Off
Jun-13-16 05:08PM  NEURALSTEM, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits
08:45AM  Neuralstem Announces New Chairman and Further Reorganization Plans GlobeNewswire
Jun-10-16 04:07PM  NEURALSTEM, INC. Files SEC form 8-K, Other Events
Jun-07-16 04:02PM  NEURALSTEM, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Other Events
Jun-06-16 04:01PM  NEURALSTEM, INC. Files SEC form 8-K, Changes in Registrant's Certifying Accountant, Financial Statements and Exhibits
May-26-16 11:11AM  These 5 Stocks Under $10 Are About to Soar Higher +6.82%
May-23-16 04:03PM  NEURALSTEM, INC. Files SEC form 8-K, Costs Associated with Exit or Disposal Activities, Regulation FD Disclosure
May-20-16 08:32AM  Neuralstem Announces Plan of Reorganization to Further Align Business with Strategic Intent PR Newswire
May-19-16 07:14PM  ETFs with exposure to Neuralstem, Inc. : May 19, 2016
May-18-16 01:26PM  Neuralstem, Inc. :CUR-US: Earnings Analysis: Q1, 2016 By the Numbers
May-13-16 04:48PM  NEURALSTEM, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Unregistered Sale of Equity Securiti
May-12-16 04:54PM  Neuralstem to Raise $1.08 Million PR Newswire
04:26PM  NEURALSTEM, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Other Events, Financial Statement
09:07AM  Neuralstem Announces First Patient Enrolled in Phase 2 Clinical Trial in Major Depressive Disorder PR Newswire
May-09-16 08:37AM  Neuralstem reports 1Q loss
08:05AM  Neuralstem Reports Fiscal First Quarter 2016 Results and Business Update PR Newswire
08:03AM  NEURALSTEM, INC. Files SEC form 10-Q, Quarterly Report EDGAR Online
Neuralstem, Inc., a clinical stage biopharmaceutical company, focuses on the research and development of nervous system therapies based on its proprietary human neuronal stem cells and small molecule compounds. The company's stem cell based technology enables the isolation and expansion of human neural stem cells from various areas of the developing human brain and spinal cord enabling the generation of physiologically relevant human neurons of various types. It is developing products include NSI-189, a chemical entity, which is in Phase II clinical trial for the treatment of major depressive disorder, as well as is in preclinical programs for the MCAO stroke, type 1 and 2 diabetes related neuropathy, irradiation-induced cognition, long-term potentiation enhancement, and angelman syndrome. The company is also developing NSI-566, which has completed Phase II clinical trial for treating amyotrophic lateral sclerosis disease, as well as is in Phase I clinical trials for the treatment of chronic spinal cord injury and motor deficits due to ischemic stroke. Neuralstem, Inc. was founded in 1996 and is headquartered in Germantown, Maryland.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Daly Richard JChief Executive OfficerMay 17Buy4.007,50030,00023,312May 18 01:02 PM
LLOYD JONES JONATHAN BRIANChief Financial OfficerMar 24Buy5.505,45530,0037,859Mar 27 04:06 PM
Daly Richard JChief Executive OfficerFeb 24Buy3.862,59110,00115,812Feb 27 04:30 PM
Daly Richard JChief Executive OfficerJan 25Buy3.522,84110,00013,221Jan 27 04:18 PM
Daly Richard JChief Executive OfficerDec 23Buy0.3132,25910,000134,939Dec 30 04:05 PM
Daly Richard JChief Executive OfficerNov 25Buy0.2835,71510,000102,680Nov 28 05:36 PM
Daly Richard JChief Executive OfficerOct 25Buy0.2835,71510,00066,965Oct 27 04:05 PM
Daly Richard JChief Executive OfficerSep 23Buy0.3231,25010,00031,250Sep 26 04:50 PM
LLOYD JONES JONATHAN BRIANChief Financial OfficerSep 23Buy0.3231,25010,00031,250Sep 26 04:51 PM